I think GSK had a stab at a herpes vaccine a few years ago. They hit a brick wall at the Phase 3 trial phase. A GSK like Big Pharma will be needed to fund late stage trials.
Will be interesting to see if authorities include a future preventative herpes vaccine on the immunization schedule. It will need to satisfy a number of requirements including whether the vaccination is a priority. Apart from neonate herpes, herpes doesnt damage any vital organs and doesnt lead to death in people so, in a world of tight health budgets and competing health priorities, it may not be considered a huge priority.
I personally believe because it has relatively minor morbidity issues I reckon the health authorities might be inclined to wait until they have years (maybe decades) of data behind it before its put on a universal vaccination schedule. It doesnt prevent people from getting a vax in the meantime, they just have to pay for it from their own pocket.
- Forums
- ASX - By Stock
- AVR
- 2:1000000 million chance of getting brain damage from Herpes
2:1000000 million chance of getting brain damage from Herpes, page-67
-
- There are more pages in this discussion • 6 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$13.02 |
Change
1.120(9.41%) |
Mkt cap ! $275.4M |
Open | High | Low | Value | Volume |
$12.00 | $13.20 | $12.00 | $610.0K | 48.39K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 59 | $12.95 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$13.00 | 104 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
3 | 319 | 12.910 |
2 | 113 | 12.900 |
1 | 1000 | 12.820 |
1 | 1000 | 12.800 |
1 | 950 | 12.700 |
Price($) | Vol. | No. |
---|---|---|
13.000 | 104 | 1 |
13.020 | 623 | 1 |
13.130 | 310 | 2 |
13.140 | 799 | 2 |
13.200 | 3000 | 1 |
Last trade - 15.18pm 11/09/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |